CA2202274A1 - Amino acid nucleic acids - Google Patents

Amino acid nucleic acids

Info

Publication number
CA2202274A1
CA2202274A1 CA002202274A CA2202274A CA2202274A1 CA 2202274 A1 CA2202274 A1 CA 2202274A1 CA 002202274 A CA002202274 A CA 002202274A CA 2202274 A CA2202274 A CA 2202274A CA 2202274 A1 CA2202274 A1 CA 2202274A1
Authority
CA
Canada
Prior art keywords
group
noh
och3
sch3
onh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002202274A
Other languages
English (en)
French (fr)
Inventor
Kandasamy Ramasamy
Guangyi Wang
Wilfried Seifert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Pharmaceuticals International Inc USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2202274A1 publication Critical patent/CA2202274A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002202274A 1994-11-02 1995-11-02 Amino acid nucleic acids Abandoned CA2202274A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33389594A 1994-11-02 1994-11-02
US08/333,895 1994-11-02

Publications (1)

Publication Number Publication Date
CA2202274A1 true CA2202274A1 (en) 1996-05-17

Family

ID=23304698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002202274A Abandoned CA2202274A1 (en) 1994-11-02 1995-11-02 Amino acid nucleic acids

Country Status (13)

Country Link
EP (1) EP0789707A4 (ru)
JP (1) JPH10508312A (ru)
KR (1) KR100393336B1 (ru)
CN (1) CN1171112A (ru)
AU (1) AU693622B2 (ru)
CA (1) CA2202274A1 (ru)
HU (1) HU218086B (ru)
MX (1) MX9703188A (ru)
PL (1) PL185852B1 (ru)
RU (1) RU2154638C2 (ru)
SI (1) SI9520112A (ru)
UA (1) UA48150C2 (ru)
WO (1) WO1996014330A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840879A (en) * 1996-12-06 1998-11-24 Wang; Edge R. Reagents and solid supports for improved synthesis and labeling of polynucleotides
AU2002256168B2 (en) * 2001-04-10 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
CA2884340C (en) * 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
WO2012074012A1 (ja) 2010-11-30 2012-06-07 独立行政法人科学技術振興機構 ヌクレオシド類縁体又はその塩、オリゴヌクレオチド類縁体、遺伝子発現抑制剤、及び遺伝子検出用核酸プローブ
RU2460721C1 (ru) * 2011-02-25 2012-09-10 Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) Способ получения амидофосфитного мономера ахиральной ненуклеотидной вставки для модификации олигонуклеотидов
DE102014007158A1 (de) * 2014-05-16 2015-11-19 Ugichem Gmbh Neue Peptid-Nukleinsäuren-Monomere und -Oligomere
US11208429B2 (en) 2017-06-16 2021-12-28 Eisai R&D Management Co., Ltd. Modified nucleic acid monomer compound and oligonucleic acid analog
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650699T2 (de) * 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf

Also Published As

Publication number Publication date
AU4234196A (en) 1996-05-31
RU2154638C2 (ru) 2000-08-20
WO1996014330A1 (en) 1996-05-17
KR970707144A (ko) 1997-12-01
JPH10508312A (ja) 1998-08-18
UA48150C2 (ru) 2002-08-15
PL185852B1 (pl) 2003-08-29
MX9703188A (es) 1997-12-31
AU693622B2 (en) 1998-07-02
EP0789707A1 (en) 1997-08-20
HU218086B (hu) 2000-05-28
KR100393336B1 (ko) 2003-12-24
SI9520112A (sl) 1998-08-31
HUT77435A (hu) 1998-04-28
EP0789707A4 (en) 1999-02-24
CN1171112A (zh) 1998-01-21
PL320084A1 (en) 1997-09-15

Similar Documents

Publication Publication Date Title
JP3739785B2 (ja) 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
US5830653A (en) Methods of using oligomers containing modified pyrimidines
US6962783B2 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5434257A (en) Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5792608A (en) Nuclease stable and binding competent oligomers and methods for their use
EP0643720A1 (en) Binding competent oligomers containing 2', 5' linkages
WO1994024144A2 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1992010590A1 (en) Inhibition of transcription by formation of triple helixes
US5969135A (en) Oligonucleotide analogs with an amino acid or a modified amino alcohol residue
CA2202274A1 (en) Amino acid nucleic acids
CA2256765A1 (en) 2'-substituted nucleosides and oligonucleotide derivatives
CZ10042U1 (cs) Nukleosidy s modifikovaným cukrem
EP0616612A1 (en) Nuclease stable and binding competent oligomers and methods for their use
US20220073916A1 (en) Novel phosphoramidites
US20220112493A1 (en) Phosphonoacetate gapmer oligonucleotides
WO2000011013A1 (en) Modified nucleomonomers and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead